Clearant Announces Second Agreement to Expand Its Direct Distribution Growth Initiative (R) for the Sports Medicine Market.

Agreement to accelerate ramp up in the usage of Clearant Process sterile implants under the direct distribution initiative; addressable market now $ 350 million per year

LOS ANGELES -- Clearant, Inc. (OCTCBB:CLRI) announced today that it signed an agreement with JPS Surgical, Inc., a leading distributor of orthopedic surgical supplies, to represent and distribute Clearant Process[R] Sterile Implants for allograft sport medicine surgeries. Under the terms of the agreement, JPS Surgical, Inc. will deploy its team of 20 sales representatives to market the implants to the sports medicine specialists throughout the states of Oklahoma and Arkansas.

"This is the second distribution agreement that we announce this month to expand our reach to surgeons in a region where Clearant does not have a direct sales force, reflecting; the growing demand for Clearant Process sterile implants by surgeons and distributors. To-date, Clearant does not have any sales representation in the states of Arkansas and Oklahoma. As a result, we are pleased to be able to complement our direct distribution initiative with a group of sales people as successful as those of JPS Surgical, Inc. This agreement will, immediately, give Clearant greater market reach in the states of Oklahoma and Arkansas and we are confident that this will lead to faster adoption for the Clearant Process sterile sports medicine implants in that region," said Clearant Chief Executive Officer Alain Delongchamp.

"Each one of our 20 sales representatives has a relationship with surgeons from every orthopedic sub-specialty, including sports medicine, arthroplasty and trauma in their individual territory thanks to our very broad product line. As our sales representatives are working with a large number of the hospital staff and orthopedic surgeons in our region, we are seeing a significant demand for safer tissue,." said Mark Farrow, President JPS Surgical, Inc. "Over the last couple of weeks, we received several orders for the Clearant Process implants from surgeons we have a relationship with.. We expect that a substantial number of the surgeons we work with will become regular users of Clearant Process implants in the near term."

Over the past two years, Clearant Process[R] Sterile Implants have achieved recognition and support in the sports medicine field due to their excellent performance and superior protection against infection. To-date, more than 9,000 patients received a Clearant Process sterile implant with success.

The Clearant Process is the first technology capable of eliminating all types of pathogens in tissue implant sterilized in its final packaging, while maintaining the integrity of the essential underlying protein in the tissue. Products processed with the Clearant Process can achieve, and even exceed, levels of sterility associated with medical devices

About Clearant, Inc.

Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected Clearant Process, which substantially reduces all types of bacteria and viruses in biological products while maintaining the functionality of the underlying tissue implant or protein. The Company began to distribute directly to surgeons, hospitals and clinics Clearant Process sterile implants in June 2006; in addition, Clearant continues to license the Clearant Process and provides its patented sterilization services to tissue banks and other biological products manufacturers. As of the end of 1Q 2006, Clearant had 10 license and service agreements with tissue banks. To date more than 9,000 patients have been successfully implanted with Clearant Process sterile implants supplied by one of the Company's licensed partners. Whereas various competing sterilization methods only kill specific types of pathogens (such as bacteria or lipid-enveloped viruses) for specific products, the Clearant Process reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. Also, the Clearant Process can be applied at various stages of product processing and/or manufacturing, including in the final packaging. For more information, please visit www.clearant.com.

About O.R. Specialties -

JPS Surgical, Inc. provides both surgical and post surgical products to hospitals, surgery centers, doctor's offices, rehab providers, and podiatrist offices. Our headquarters are in Tulsa, Oklahoma. Our surgical division is made up of tenured professional consultants that specialize in orthopedic sports medicine, trauma, joint replacement, and podiatric surgical procedures.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, in particular statements regarding surgeons strongly recommending the use of implants with tissue treated by the CLEARANT PROCESS, and the conclusions from a study by surgeons to build demand for sterilized tissue. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, results of additional clinical studies, acceptance and success of our direct distribution of allografts, efficacy of the technology, intense competition and substantial regulation in the biotechnology industry, and additional risks discussed in the company's filings with the SEC, available on the SEC web site http://www.sec.gov.